LL-37: How It Works, What It's Studied For & Safety
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid cationic peptide studied for antimicrobial, immunomodulatory, and wound-healing effects. Clinicians consider it for chronic and recurrent infection research (Lyme co-infections, biofilm-related conditions). Not FDA-approved; dispensed by Wells Pharmacy Network only after a clinician evaluation.
Also known as: Cathelicidin LL-37, hCAP-18 C-terminal fragment
How does LL-37 work?
LL-37 is cleaved from the precursor hCAP-18 by neutrophil and epithelial proteases. It disrupts microbial membranes (broad-spectrum antibacterial, antiviral, antifungal activity) and modulates host immunity by chemoattracting immune cells, neutralizing LPS, and influencing wound-healing signaling.
What is LL-37 studied for?
- Chronic and recurrent infection research (Lyme co-infections, biofilm-related conditions)
- Wound-healing and dermatologic research
- Innate-immunity research and adjunct in clinician-directed immunomodulation protocols
How is LL-37 taken?
Compounded as a subcutaneous injection in clinician-directed protocols. Not FDA-approved.
Is LL-37 FDA-approved? Is it safe?
Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. Reported research effects include injection-site reactions and transient flu-like symptoms. Because LL-37 has been implicated in some autoimmune conditions (e.g. psoriasis, lupus pathophysiology), clinician judgment is appropriate in autoimmune patients. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.
In the Regen Therapy catalog
This compound does not currently appear in an active Regen Therapy protocol. Browse the full catalog for adjacent options.
What does the research say about LL-37?
Substantial in-vitro and animal antimicrobial and immunomodulatory data; controlled human clinical-outcome trials are limited.
Citations & further reading
Considering LL-37 as part of a protocol?
Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.
Browse the catalog →